Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6811 to 6825 of 7681 results

  1. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

  2. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued [GID-TA10110]

  3. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

  4. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued [GID-TAG320]

  5. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued [GID-TA10697]

  6. Peramivir for treating influenza [ID828]

    Discontinued [GID-TA10155]

  7. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    In development [GID-TA10185] Expected publication date: TBC

  8. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued [GID-TAG422]

  9. Workplace health for employees with disabilities and long-term conditions

    Discontinued [GID-PHG58]

  10. Inpatient mental health settings

    Discontinued [GID-SGWAVE0701]

  11. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued [GID-TA10154]

  12. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]